Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiotepa + pirtobrutinib + sintilimab
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
thiotepa + pirtobrutinib + sintilimab is a combination therapy being investigated by Zhejiang Cancer Hospital for the treatment of primary or secondary central nervous system lymphoma (CNSL), particularly in frail or relapsed/refractory patients. This regimen, often referred to as TPS, combines three distinct therapeutic approaches: thiotepa, a cytotoxic alkylating agent that cross-links DNA to inhibit cell division; pirtobrutinib, a next-generation, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor designed to overcome resistance seen with covalent BTK inhibitors; and sintilimab, a humanized monoclonal antibody targeting the PD-1 receptor to restore T-cell mediated anti-tumor immune responses. The combination aims to leverage the blood-brain barrier-penetrating capabilities of thiotepa and pirtobrutinib alongside the immune-modulating effects of sintilimab to improve outcomes in difficult-to-treat CNS lymphomas.
- Other names
- Thiotepa, Pirtobrutinib, and Sintilimab combination
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on thiotepa + pirtobrutinib + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thiotepa + pirtobrutinib + sintilimab.